| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Across the last three months, Pharvaris N.V.'s insiders have reduced their positions by a net 559,502 shares worth roughly $20.4M.
Classified under Biotechnology (Healthcare sector), PHVS's insider flows are most useful compared with peers in the same group.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CEO | 650.0K | $22.75M | - | |
| Dir | 115.2K | $4.17M | - | |
| CFO | 113.8K | - | - | |
| Pres | 110.0K | $3.42M | - | |
| Other | 74.0K | $2.83M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| May 18, 2026 | Modig Berndt | Chief Executive Officer | Sell10b5-1 | 2,292 | $29.22 | $66,976.82 | -1.6% | +22.6% | - | |
| May 15, 2026 | Souverijns Wim | Chief Commercial Officer | Sell10b5-1 | 10,000 | $29.92 | $299,163.00 | -18.1% | +12.0% | - | |
| May 15, 2026 | Abele Stefan Andreas | Chief Technical Ops Officer | Sell | 8,748 | $29.82 | $260,864.49 | -19.9% | +12.0% | - | |
| May 15, 2026 | Glassman Robert | Director | Sale+OE | 10,000 | $29.82 | $298,245.40 | -48.8% | +12.0% | - | |
| May 1, 2026 | Lu Peng | Chief Medical Officer | Sale+OE10b5-1 | 14,166 | $30.17 | $427,418.57 | -17.7% | +15.1% | - | |
| Apr 30, 2026 | Lesage Anne | Chief Early Development | Sale+OE10b5-1 | 48,300 | $30.23 | $1,459,970.16 | -26.5% | +5.2% | - | |
| Apr 30, 2026 | Lu Peng | Chief Medical Officer | Sale+OE10b5-1 | 18,733 | $30.21 | $565,859.27 | -22.1% | +5.2% | - | |
| Apr 30, 2026 | Schikan Johannes Gerardus Christiaan Petrus | Director | Sell10b5-1 | 32,900 | $30.29 | $996,544.70 | -8.5% | +5.2% | - | |
| Apr 23, 2026 | Lesage Anne | Chief Early Development | Sale+OE10b5-1 | 14,700 | $30.05 | $441,725.60 | -20.7% | +25.9% | - | |
| Apr 23, 2026 | Schikan Johannes Gerardus Christiaan Petrus | Director | Sell10b5-1 | 7,100 | $30.05 | $213,381.70 | -1.8% | +25.9% | - |